Cabotegravir 600mg/3mL
| Product Overview | |
| Generic Name | Cabotegravir 600mg/3mL |
| Brand Name(s) | APRETUDE |
| Form | 3mL Injectable |
| Strength | 600 mg/3mL |
| Therapeutic Class | Antiretroviral agent; HIV integrase strand transfer inhibitor, or INSTI |
| ATC Code | J05AJ04 |
| Manufacturing & Regulatory | |
| Manufacturer | Cipla, Viatris |
| Country | Canada, India |
| GMP Compliance | WHO-GMP |
| COFEPRIS | Under Registration (2025) |
| Logistics & Export | |
| MOQ | 10 units |
| Shelf Life | 18 - 24 meses |
| Storage | Store at 2°C to 25°C. Excursions up to 30°C are permitted. Do not freeze |
| Incoterms | EXW |
| Lead Time | 7 - 10 Business Days |
| Documentation | |
| Certificate of Analysis (COA) | Supplied per batch upon request |
Description
Cabotegravir extended-release injectable suspension for HIV-1 pre-exposure prophylaxis use, subject to local regulatory/clinical requirements. The product is a cabotegravir extended-release injectable suspension and does not require dilution or reconstitution before administration. It is administered by gluteal intramuscular injection
